- Trials with a EudraCT protocol (126)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (21)
126 result(s) found for: ARDS.
Displaying page 1 of 7.
EudraCT Number: 2022-002494-28 | Sponsor Protocol Number: 6 | Start Date*: 2023-05-18 | |||||||||||
Sponsor Name:Consorcio Centro de Investigacion Biomedica en Red, (CIBER) | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
Medical condition: Intensive Care Unit patients with Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005306-25 | Sponsor Protocol Number: Pioneer | Start Date*: 2021-09-15 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial (PIONEER) GR-2019-12371063 | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001078-27 | Sponsor Protocol Number: 19999 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) BE (Completed) DK (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002022-20 | Sponsor Protocol Number: NL61945.029.17 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mil... | |||||||||||||
Medical condition: We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005260-15 | Sponsor Protocol Number: FPCLI002 | Start Date*: 2016-02-10 | |||||||||||
Sponsor Name:Faron Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... | |||||||||||||
Medical condition: Adult patients diagnosed with moderate or severe Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006644-27 | Sponsor Protocol Number: CARR-ARDS-2021 | Start Date*: 2023-02-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE | |||||||||||||
Full Title: Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002913-16 | Sponsor Protocol Number: 0135-0347 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome caused by Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000775-17 | Sponsor Protocol Number: PI11-0143 | Start Date*: 2012-11-21 | |||||||||||
Sponsor Name:Jesús Villar Hernández | |||||||||||||
Full Title: A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients with the Acute Respiratory Distress Syndrome | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000140-13 | Sponsor Protocol Number: FPCLI001 | Start Date*: 2008-05-09 |
Sponsor Name:Faron Pharmaceuticals Limited | ||
Full Title: A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acut... | ||
Medical condition: Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002564-32 | Sponsor Protocol Number: 14043DMcA-AS | Start Date*: 2014-10-27 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: ASpirin as a Treatment for ARDS (STAR) trial: a randomised, double-blind, allocation concealed, placebo-controlled phase 2 trial. | ||
Medical condition: Acute respiratory distress syndrome | ||
Disease: | ||
Population Age: Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-002867-16 | Sponsor Protocol Number: 2017-42 | Start Date*: 2017-10-05 |
Sponsor Name:Assistance Pubique Hôpitaux de Marseille | ||
Full Title: Procollagen-3 driven corticosteroids for persistent Acute Respiratory Distress Syndrome | ||
Medical condition: Acute Respiratory Distress Syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001529-88 | Sponsor Protocol Number: LOC 04/2004-01 | Start Date*: 2004-11-08 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Dose efficacy relation of inhalative prostaglandin I2 vs. inhalative prostaglandin E1 in patients with ARDS: comparison of efficacy with respect to paO2/FiO2 ratio, Qs/Qt and PAP. | ||
Medical condition: Patients suffering from ARDS who need in the moment of enrolment artificial respiration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-003923-40 | Sponsor Protocol Number: APHP200019 | Start Date*: 2021-01-08 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP) | |||||||||||||
Full Title: A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ... | |||||||||||||
Medical condition: Sepsis complicated by ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005863-29 | Sponsor Protocol Number: HelmetHeparin | Start Date*: 2021-07-15 | |||||||||||||||||||||
Sponsor Name:ASST FATEBENEFRATELLI SACCO | |||||||||||||||||||||||
Full Title: Nebulised heparin in COVID-19-related ARDS patients undergoing non-invasive ventilation with helmet cPAP: a prospective, randomised, double blind, placebo-controlled, multicentre study | |||||||||||||||||||||||
Medical condition: COVID-19-related Acute Respiratory Distress Syndrome (ARDS) patients undergoing non-invasive ventilation with helmet continuous positive airway pressure (cPAP) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000598-95 | Sponsor Protocol Number: HS-20-674 | Start Date*: 2021-07-30 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002122-82 | Sponsor Protocol Number: UKER-COV2-01 | Start Date*: 2020-06-12 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Erlangen | ||||||||||||||||||
Full Title: Prospective open-label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID-19 convalescent plasma plus standard t... | ||||||||||||||||||
Medical condition: ARDS due to COVID-19 necessitating invasive mechanical ventilation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002647-86 | Sponsor Protocol Number: BALTI-2, Version 2 | Start Date*: 2006-09-25 |
Sponsor Name:Heart of England NHS Foundation Trust [...] | ||
Full Title: BALTI-2: Beta Agonists in Lung Injury Trial | ||
Medical condition: Acute respiratory distress syndrome (ARDS) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001307-16 | Sponsor Protocol Number: SIC | Start Date*: 2020-04-01 |
Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal | ||
Full Title: Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. | ||
Medical condition: Adult respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005887-70 | Sponsor Protocol Number: REMED | Start Date*: 2021-01-28 |
Sponsor Name:Fakultní nemocnice Brno | ||
Full Title: Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomized controlled trial | ||
Medical condition: Acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001612-25 | Sponsor Protocol Number: REP0122 | Start Date*: 2022-10-12 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with ... | |||||||||||||
Medical condition: Acute Respiratory Distress Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.